In short
A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of a novel gene therapy approach for treating Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). This study focuses on using modified stem cells and T-cells to potentially replace traditional transplant methods, offering hope for improved outcomes and reduced complications for patients with this rare genetic disorder.
At a glance
- Study Type
- Phase I/II, Open Label, Non-Randomized, Monocentric, Single Arm
- Condition
- Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)
- Intervention
- Gene therapy using modified autologous CD34+ cells (MUNC-CD34) and T-cells (MUNC-T3)
- Primary Outcomes
- Transplant-related mortality, adverse events, malignancy incidence, detection of replication-competent lentivirus
- Secondary Outcomes
- Blood cell recovery, gene integration, protein expression, immune cell function, complications, cost analysis
- Follow-up Duration
- Up to 60 months post-treatment
What is MUNC-T3?
MUNC-T3 is an innovative gene therapy treatment being studied for patients with a rare genetic condition called Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). This therapy is part of a clinical trial that aims to provide a new treatment option for patients who may not respond well to current treatments or who have experienced complications from other therapies.
Target Condition: Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)
Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3) is a rare genetic disorder that affects the immune system. In this condition, the body's immune cells don't work properly, leading to severe inflammation and other health problems. FHL 3 is caused by mutations in a gene called UNC13D, which is important for the normal function of immune cells.
How MUNC-T3 Works
MUNC-T3 is a type of gene therapy that aims to correct the underlying genetic problem in FHL 3 patients. Here's a simplified explanation of how it works:
- The therapy uses the patient's own cells, specifically a type of stem cell called CD34+ cells and T-cells (a type of immune cell).
- These cells are collected from the patient and modified in a laboratory to carry a correct version of the UNC13D gene.
- The modified cells are then given back to the patient through an intravenous (IV) infusion.
- The goal is for these modified cells to produce a normal version of the Munc13.4 protein (which is made by the UNC13D gene), helping to correct the immune system problem.
Treatment Process
The treatment involves two main components:
- MUNC-CD34: This is the modified stem cell component. Patients receive at least 2 million CD34+ cells per kilogram of body weight, with a maximum dose of 20 million cells per kilogram. These cells are given through an IV on day 0 of the treatment.
- MUNC-T3: This is the modified T-cell component. Patients receive between 10,000 and 5 million T-cells per kilogram of body weight. These cells are given through an IV on day 14 after the initial treatment, and possibly again on day 28 if needed.
Potential Benefits
The researchers hope that MUNC-T3 therapy will offer several advantages over current treatments:
- Avoiding complications associated with donor stem cell transplants, such as graft-versus-host disease (where donor cells attack the patient's body) and difficulties with engraftment (when donor cells fail to grow in the patient's body).
- Reducing the risk of severe side effects from the conditioning process (preparation for transplant).
- Providing immediate support to fight infections, especially viral infections that often trigger FHL 3 symptoms.
- Potentially improving overall survival and event-free survival (time without major health events) for patients.
Safety and Monitoring
As with any new treatment, safety is a top priority. The clinical trial is closely monitoring patients for any side effects or complications. Some key safety measures include:
- Monitoring for any treatment-related mortality up to 6 months after therapy.
- Tracking the frequency and severity of side effects for up to 60 months (5 years).
- Checking for any signs of abnormal cell growth or cancer development.
- Testing for the presence of replication-competent lentivirus (the virus used to modify the cells) at regular intervals.
Ongoing Research
The clinical trial for MUNC-T3 is ongoing and will be collecting data on various aspects of the treatment, including:
- How quickly patients' blood cell counts recover after treatment.
- The amount of corrected gene present in the patients' cells over time.
- The function of the patients' immune cells after treatment.
- The overall health outcomes for patients, including any need for intensive care and the occurrence of infections or other complications.
This research will help determine how effective MUNC-T3 is in treating FHL 3 and whether it could become a standard treatment option in the future.